All relevant data are within the manuscript but additional queries can be conducted using the Microbiology Visualization Platform (<https://sentry-mvp.jmilabs.com/>). This was cited in the data analyses section of the manuscript.

Introduction {#sec001}
============

Urinary tract infections (UTIs) caused by pathogens such as *Escherichia coli*, the most prevalent UTI pathogen, have been historically managed with oral antibiotics including the cephalosporins, trimethoprim-sulfamethoxazole (TMP-SMX) and the fluoroquinolones. Unfortunately, in recent years we have seen the utility of many of these agents being eroded because of widespread use and the subsequent development of resistance \[[@pone.0220265.ref001]\]. When ciprofloxacin was first introduced in the mid-1980s resistance among UTI isolates of *E*. *coli* was nonexistent (\<1%)\[[@pone.0220265.ref002]\]. Fluoroquinolone-resistant *E*. *coli* has progressively increased in the United States from 1.2% in 1998 \[[@pone.0220265.ref002]\] to 25% in 2012--2014 \[[@pone.0220265.ref003]\]. Furthermore, resistance to trimethoprim-sulfamethoxazole among UTI isolates of *E*. *coli* has also increased from 7 to 9% \[[@pone.0220265.ref004]\] in 1989 to 1992 to 30% in 2009 to 2013 \[[@pone.0220265.ref005]\].

The increasing prevalence of the extended spectrum β-lactamases (ESBLs) among Gram-negative organisms also seriously compromises the activity of the cephalosporins such as ceftriaxone that is recommended for treatment of pyelonephritis \[[@pone.0220265.ref006]\] and many of the oral agents used to treat UTIs such as cefuroxime \[[@pone.0220265.ref007]\]. ESBL-producing *E*. *coli* pose additional risk factors including longer duration of hospital stay \[[@pone.0220265.ref008]\]. Of particular concern are the high levels of antimicrobial co-resistance among ESBL-producing organisms that includes many of the oral agents used to treat UTIs \[[@pone.0220265.ref009], [@pone.0220265.ref010]\]. A particular driver of the rapid rise of ESBL-based resistance is the expansion of the ST131-H30 clone of *E*. *coli* that is well established as a globally disseminated multidrug resistant clone \[[@pone.0220265.ref011], [@pone.0220265.ref012]\]. The ST131 clone is frequently associated with the CTX-M-15 ESBL which is now the most prevalent ESBL in the US and many other countries \[[@pone.0220265.ref013], [@pone.0220265.ref014]\]. In addition, ST131-H30 isolates are uniformly fluoroquinolone-resistant due to conserved replacement mutations in *gyrA* and *parC* \[[@pone.0220265.ref015]\] which are responsible for the millions fluoroquinolone and cephalosporin-resistant infections being reported globally \[[@pone.0220265.ref016]\]. Moreover, this clone has also been associated with a higher rate of persistent UTI, adverse outcomes and empiric antimicrobial therapy failure \[[@pone.0220265.ref017], [@pone.0220265.ref018]\].

Surveillance studies with isolates collected from 2009 to 2011 have shown that the only agents that remain highly active against ESBL-producing *E*. *coli* and other common uropathogens are the intravenous carbapenems because of their inherent stability to β-lactamases other than carbapenemase enzymes \[[@pone.0220265.ref019]\]. The goal for this study was to assess the prevalence of ESBL phenotypes and genotypes among UTI isolates of *E*. *coli* collected in the USA in 2017, and the impact of co-resistance to widely used oral agents such as the fluoroquinolones and trimethoprim-sulfamethoxazole. The study also evaluated the activity of the intravenous carbapenems to determine if they remain highly active against ESBL-producing and fluoroquinolone-resistant organisms.

Materials and methods {#sec002}
=====================

Bacterial isolates {#sec003}
------------------

A total of 1831 isolates of *E*. *coli* were collected from 30 participating medical centers that were geographically distributed among the 9 USA Census divisions in 2017 as part of the SENTRY surveillance platform (JMI Laboratories, North Liberty, IA, USA). The isolates evaluated in this study were collected from patients with urinary tract infections according to defined protocols \[[@pone.0220265.ref020]\]. The majority of the isolates were isolates from urine (n = 1449) and 132 isolates were isolated from patients with a ureteral (Foley) catheter. The isolates were from both nosocomial and community-acquired infections and included complicated and uncomplicated UTIs. Only isolates determined to be significant by local criteria as the reported probable cause of infection were included in the study. Species identification was confirmed using standard biochemical tests and using a MALDI Biotyper (Bruker Daltronics, Billerica, MA) according to the manufacturer's instructions \[[@pone.0220265.ref021]\].

Susceptibility testing {#sec004}
----------------------

All isolates were centrally tested (JMI Laboratories, North Liberty, IA) using the broth microdilution method in accordance with CLSI guidelines. In particular, the antibiotics evaluated in the study included various oral antibiotics routinely used to treat UTIs including the cephalosporins, fluoroquinolones and trimethoprim-sulfamethoxazole, as well as the intravenous carbapenems and other agents used to treat UTIs. ESBL phenotypes were determined in accordance with CLSI MIC screening criteria, as previously described \[[@pone.0220265.ref022]\]. CLSI susceptibility interpretive criteria for the Enterobacteriaceae were used to determine susceptibility and resistance rates for all agents where appropriate, including for determining the fluoroquinolone- and trimethoprim-sulfamethoxazole-resistant subsets (CLSI M100-S28) \[[@pone.0220265.ref023]\]

Resistant subsets and β-lactamase screening {#sec005}
-------------------------------------------

Isolates were screened *in silico* for narrow- and extended-spectrum β-lactamases, including carbapenemases and isolates that met ESBL MIC screening criteria were further analyzed using molecular methods (Next-Generation Sequencing; NGS) to identify specific β-lactamase genes such as *bla*~CTX-M-15~. The usual β-lactamase profiles observed in these surveillance studies have been previously published \[[@pone.0220265.ref022], [@pone.0220265.ref024], [@pone.0220265.ref025]\]. For NGS, DNA extracts were quantified using the Qubit High Sensitivity DS-DNA assay (Invitrogen/Thermo Fisher, Inc) and normalized to 0.2 ng/μL. A total of 1 ng of high-quality genomic DNA was used as input material for library construction using the Nextera XT DNA library preparation kit (Illumina, San Diego, CA). Libraries were normalized using the bead-based normalization procedure (Illumina) and sequenced on MiSeq. Fastq files generated were assembled using SPAdes Assembler and subjected to proprietary software (JMI Laboratories) for screening of β-lactamase genes \[[@pone.0220265.ref021]\].

Data analyses {#sec006}
-------------

All data and analysis reported in this study were conducted using the publicly available Microbiology Visualization Platform (<https://sentry-mvp.jmilabs.com/>). This freely available online tool provides query and analysis capability of the SENTRY Antimicrobial Surveillance Program database and it was used for this study to generate national and regional resistance rates and analyze co-resistance for the ESBL phenotypes as well as the susceptibility results for the *bla*~CTX-M-15~ genotypes of *E*. *coli*.

Results {#sec007}
=======

Susceptibility of all UTI isolates of *E*. *coli* collected in the USA during 2017 {#sec008}
----------------------------------------------------------------------------------

The results in [Table 1](#pone.0220265.t001){ref-type="table"} show the susceptibility results for different antimicrobial agents against the 1831 isolates of *E*. *coli* collected from UTI patients. Resistance to levofloxacin and ciprofloxacin were observed in 24.3% and 25.8% of isolates, respectively. A TMP-SMX resistance phenotype was noted in 32.1% of isolates. Using the oral breakpoints for cefuroxime, 15.9% of isolates were resistsant. In contrast, the intravenous carbapenems including doripenem, ertapenem, imipenem and meropenem were all highly active (≥99.4% susceptible) with little or no resistance being observed. Among other agents, amikacin was also one of the most active agents with only 0.1% of the UTI isolates of *E*. *coli* being resistant. Ampicillin-sulbactam was among one of the least active agents with 28.7% of the isolates being resistant.

10.1371/journal.pone.0220265.t001

###### Susceptibility results for 1831 isolates of *E*. *coli* from urinary tract infections collected in the USA in 2017 (SENTRY Antimicrobial Surveillance Program).

![](pone.0220265.t001){#pone.0220265.t001g}

  Agent                            MIC (μg/mL)    %S[^a^](#t001fn001){ref-type="table-fn"}      %I[^a^](#t001fn001){ref-type="table-fn"}   %R[^a^](#t001fn001){ref-type="table-fn"}          
  -------------------------------- -------------- --------------------------------------------- ------------------------------------------ ------------------------------------------ ------ ---------------------------------------------
  Levofloxacin                     ≤0.03--\>16    ≤0.03                                         16                                         74.2                                       1.5    24.3
  Ciprofloxacin                    ≤0.03--\>4     ≤0.03                                         \>4                                        73.9                                       0.3    25.8
  Trimethroprim-sulfamethoxazole   ≤0.5--\>8      ≤0.5                                          \>8                                        67.9                                       \-     32.1
  Cefuroxime                       ≤0.12--\>64    4                                             \>64                                       63.2                                       20.9   15.9 [^b^](#t001fn002){ref-type="table-fn"}
  80.3                             3.8            15.9 [^c^](#t001fn003){ref-type="table-fn"}                                                                                                
  Amoxicillin-clavulanate          0.5--\>32      8                                             16                                         77.9                                       16.4   5.8
  Ampicillin-sulbactam             ≤0.5--\>64     8                                             64                                         54.1                                       17.3   28.7
  Piperacillin-tazobactam          ≤0.06--\>128   2                                             4                                          97.8                                       1.3    0.9
  Doripenem                        ≤0.06--1       ≤0.06                                         ≤0.06                                      100                                        0.0    0.0
  Ertapenem                        ≤0.008--2      ≤0.008                                        0.03                                       99.4                                       0.3    0.2
  Imipenem                         ≤0.12--1       ≤0.12                                         0.25                                       100                                        0.0    0.0
  Meropenem                        ≤0.015--1      ≤0.015                                        0.03                                       100                                        0.0    0.0
  Cefepime                         ≤0.12--\>16    ≤0.12                                         8                                          88.6                                       2.6    8.8 [^d^](#t001fn004){ref-type="table-fn"}
  Ceftazidime                      0.03--\>32     0.25                                          8                                          89.0                                       2.5    8.5
  Amikacin                         1--\>32        2                                             4                                          99.7                                       0.2    0.1
  Gentamicin                       0.25--\>16     0.5                                           \>16                                       87.7                                       0.4    11.9
  Doxycycline                      0.25--\>8      1                                             \>8                                        72.4                                       7.9    19.7
  Minocycline                      0.25--\>32     1                                             8                                          86.9                                       6.3    6.8
  Tetracycline                     0.5--\>16      2                                             \>16                                       70.2                                       0.1    29.7

^a^2018 CLSI Interpretive criteria, %S = percent susceptible, %I = percent intermediate, %R = percent resistant

^b^Using oral breakpoints

^c^Using parenteral breakpoints

^d^Intermediate interpreted as susceptible-dose-dependent

Prevalence of ESBL phenotypes of *E*. *coli* and co-resistance to widely used oral antimicrobial agents {#sec009}
-------------------------------------------------------------------------------------------------------

[Fig 1](#pone.0220265.g001){ref-type="fig"} shows the national and regional prevalence of ESBL phenotypes, levofloxacin-resistant and TMP-SMX-resistant isolates of *E*. *coli* from UTIs in the USA in 2017. There were 287 (15.7%) out of the 1831 isolates of *E*. *coli* identified as ESBL phenotypes. ESBL phenotypes were identified among isolates from all US Census regions and ranged from 10.5% in West North Central region to 29.6% in the mid-Atlantic region. The national prevalence of levofloxacin-resistant among *E*. *coli* from UTIs was 24.3% and ranged from 18% in the Mountain region to 38.1% in the mid-Atlantic region. The national prevalence of TMP-SMX-resistant *E*. *coli* was 32.1% and ranged from 26.8% in East North Central to 43.5% in the mid-Atlantic. The mid-Atlantic region exhibited the highest burden of resistance among UTI *E*. *coli* among all the Census regions.

![National and regional prevalence of ESBL phenotypes, levofloxacin- and trimethoprim-sulfamethoxazole-resistant phenotypes among 1831 isolates of *E*. *coli* from UTIs in the USA in 2017.\
ESBL = extended spectrum β-lactamase, LEVO-R = levofloxacin-resistant, TMP-SMX-R = trimethoprim-sulfamethoxazole-resistant.](pone.0220265.g001){#pone.0220265.g001}

ESBL phenotypes were further analyzed as a subgroup to evaluate the extent of co-resistance to other agents including oral agents widely used to treat UTIs. The results in [Fig 2](#pone.0220265.g002){ref-type="fig"} show the resistance rates among the 287 ESBL phenotypes of *E*. *coli* from UTIs in the USA during 2017. Not surprisingly, 93.6% of the ESBL phenotypes were resistant to cefuroxime. High resistance rates were also observed for ciprofloxacin and levofloxacin at 71.8% and 67.9%, respectively. There was also high resistance to TMP-SMX with 56.1% of the ESBL phenotypes being resistant. In contrast, the agents with the lowest resistance rates were the intravenous carbapenems with none of the isolates being resistant to doripenem, imipenem and meropenem and only 1.4% of isolates being resistant to ertapenem.

![Antibiotic resistance among 287 ESBL phenotypes of UTI isolates of *E*. *coli* collected in the USA in 2017.](pone.0220265.g002){#pone.0220265.g002}

[Fig 3](#pone.0220265.g003){ref-type="fig"} shows the prevalence of levofloxacin, TMP-SMX and meropenem resistance rates among ESBL isolates of *E*. *coli* across the 9 Census regions. The national prevalence of levofloxacin-resistance was 67.9% and ranged from 52.6% in East North Central to 82.4% in the East South Central region. Similarly, the national prevalence of TMP-SMX resistance was 59.2% and ranged from 36.8% in West South Central to 74.2% in the mid-Atlantic region. No meropenem-resistant UTI isolates of *E*. *coli* were identified in any of the Census regions.

![Resistance to meropenem, levofloxacin and trimethoprim-sulfamethoxazole among 287 ESBL phenotypes of *E*. *coli* from UTIs in the USA in 2017 according to Census region.](pone.0220265.g003){#pone.0220265.g003}

Co-resistance among fluoroquinolone-resistant and TMP-SMX-resistant *E*. *coli* {#sec010}
-------------------------------------------------------------------------------

The results in [Table 2](#pone.0220265.t002){ref-type="table"} show the resistance profiles of isolates that are either resistant to levofloxacin or TMP-SMX. Among the levofloxacin-resistant *E*. *coli* co-resistance was observed for cefuroxime with 45.7% resistance and for TMP-SMX with 56.2% of the isolates being reported as resistant. Similarly, for the TMP-SMX-resistant isolates of *E*. *coli* 31.3% were co-resistant to cefuroxime and 42.5% co-resistant to levofloxacin. In contrast, little or no resistance was observed for the carbapenems against levofloxacin and/or TMP-SMX-resistant isolates.

10.1371/journal.pone.0220265.t002

###### Co-resistance among trimethoprim-sulfamethoxazole-resistant and levofloxacin-resistant *E*. *coli* from urinary tract infections collected in the USA in 2017.

![](pone.0220265.t002){#pone.0220265.t002g}

  Agent                           Percent co-resistance among UTI isolates of *E*. *coli* resistant to:   
  ------------------------------- ----------------------------------------------------------------------- ------
  Cefuroxime                      31.3                                                                    45.7
  Ceftazidime                     15.0                                                                    24.7
  Ciprofloxacin                   44.2                                                                    100
  Levofloxacin                    42.5                                                                    100
  Doripenem                       0.0                                                                     0.0
  Ertapenem                       0.3                                                                     0.5
  Imipenem                        0.0                                                                     0.0
  Meropenem                       0.0                                                                     0.0
  Trimethoprim-sulfamethoxazole   100                                                                     56.2

Susceptibility of *bla*~CTX-M-15~ genotypes of UTI isolates of *E*. *coli* {#sec011}
--------------------------------------------------------------------------

The *bla*~CTX-M-15~ genotypes were identified among 151 of the UTI isolates of *E*. *coli* collected in the USA during 2017 and were the most prevalent ESBLs identified accounting for 59% of the ESBL phenotypes. The next most prevalent β-lactamase was OXA-1/30 but in most isolates was co-expressed among CTX-M-15 positive isolates. The susceptibility results for various antimicrobial agents are shown in [Table 3](#pone.0220265.t003){ref-type="table"}. The isolates were highly resistant to the fluoroquinolones with resistance rates of 81.5% and 83.4%, respectively, for levofloxacin and ciprofloxacin. High resistance was also observed for TMP-SMX (69.5%) and cefuroxime (100%). High resistance rates were also observed for many of the other agents tested with the exception of the carbapenems where none of the isolates were resistant and amikacin where 1.3% of the isolates were resistant.

10.1371/journal.pone.0220265.t003

###### Activity of antimicrobial agents against confirmed CTX-M-15 β-lactamase-producing isolates of *E*. *coli* collected from UTIs in the USA during 2017.

![](pone.0220265.t003){#pone.0220265.t003g}

  Antimicrobial Agent             MIC (μg/mL)   %S[^a^](#t003fn001){ref-type="table-fn"}    %I[^a^](#t003fn001){ref-type="table-fn"}   %R[^a^](#t003fn001){ref-type="table-fn"}   
  ------------------------------- ------------- ------------------------------------------- ------------------------------------------ ------------------------------------------ --------------------------------------------
  Levofloxacin                    ≤0.03--\>16   \>16                                        17.2                                       1.3                                        81.5
  Ciprofloxacin                   ≤0.03--\>4    \>4                                         15.2                                       1.3                                        83.4
  Trimethoprim-sulfamethoxazole   ≤0.5--\>8     \>8                                         30.5                                       \-                                         69.5
  Cefuroxime                      \>64          \>64                                        0.0                                        0.0                                        100[^b^](#t003fn002){ref-type="table-fn"}
  0.0                             0.0           100[^c^](#t003fn003){ref-type="table-fn"}                                                                                         
  Amoxicillin-clavulanate         4--32         32                                          34.8                                       52.2                                       13.0
  Ampicillin-sulbactam            4--\>64       64                                          8.6                                        19.9                                       71.5
  Piperacillin-tazobactam         0.25--\>128   32                                          89.4                                       6.6                                        4.0
  Doripenem                       ≤0.06--0.5    ≤0.06                                       100                                        0.0                                        0.0
  Ertapenem                       ≤0.008--1     0.25                                        97.1                                       2.9                                        0.0
  Imipenem                        ≤0.12--0.5    ≤0.12                                       100                                        0.0                                        0.0
  Meropenem                       ≤0.015--0.5   0.06                                        100                                        0.0                                        0.0
  Cefepime                        1--\>16       \>16                                        9.3                                        9.9                                        80.8[^d^](#t003fn004){ref-type="table-fn"}
  Ceftazidime                     1--\>32       \>32                                        14.6                                       13.2                                       72.2
  Amikacin                        1--\>32       8                                           96.7                                       2.0                                        1.3
  Gentamicin                      0.5--\>16     \>16                                        57.0                                       0.0                                        43.0
  Doxycycline                     0.5--\>8      \>8                                         37.1                                       18.6                                       44.3
  Minocycline                     0.5--\>32     16                                          74.3                                       8.6                                        17.1
  Tetracycline                    1--\>16       \>16                                        32.9                                       0.0                                        67.1

^a^2018 CLSI Interpretive criteria; %S = percent susceptible, %I = percent intermediate, %R = percent resistant

^b^Using oral breakpoints

^c^Using parenteral breakpoints

^d^Intermediate interpreted as susceptible-dose-dependent

Discussion {#sec012}
==========

While oral antibiotics have been a mainstay of therapy for treating UTI's the results from this study show that levofloxacin and/or TMP-SMX resistance rates are ≥ 24% among UTI isolates of *E*. *coli* collected in the US during 2017. This increase in resistance suggests that considerable caution should be exercised when choosing to use the fluoroquinolones as their widespread use has resulted in being implicated as a "smoking gun" due to their role in promoting resistance \[[@pone.0220265.ref026]\]. This increase in fluoroquinolone-resistance among UTI isolates of *E*. *coli* is now resulting in calls to combat their use as first choice agents \[[@pone.0220265.ref027]\]. In this study fluoroquinolone resistance among UTI isolates of *E*. *coli* was also geographically distributed across all nine Census regions. The mid-Atlantic region exhibited the highest prevalence of levofloxacin-resistant isolates of *E*. *coli* (38.1%) and is consistent with prevalence data from other studies \[[@pone.0220265.ref005], [@pone.0220265.ref014], [@pone.0220265.ref028]\].

This study also showed the prevalence of ESBL phenotypes of *E*. *coli* from UTIs was 15.7% and many of these isolates exhibited considerable co-resistance to many of the currently available oral agents. Furthermore, *bla*~CTX-M-15~ was the most prevalent genotype among the UTI isolates of *E*. *coli* accounting for 59% of the ESBL phenotypes. The increase in prevalence of ESBLs is likely due to the widespread use of the cephalosporins \[[@pone.0220265.ref029]\]. Another possible factor for the increased prevalence of ESBL phenotypes of *E*. *coli* is the global dissemination of the ST131 clone that frequently carries *bla*~CTX-M-15~ \[[@pone.0220265.ref030]\]. In particular, *E*. *coli* 025b:H4/ST131 is now prevalent in long term care facilities, exhibits co-resistance to the fluoroquinolones, aminoglycosides and TMP-SMX, and now represents a considerable public health concern \[[@pone.0220265.ref011], [@pone.0220265.ref012]\]. The factors responsible for the successful global dissemination of *E*. *coli* ST131 remain to be elucidated but may be due to the type I fimbrial adhesins that may allow it to colonize the gastrointestinal tract more efficiently \[[@pone.0220265.ref031]--[@pone.0220265.ref033]\].

The ESBL phenotypes of *E*. *coli* reported in this study were geographically distributed across the nine Census regions with the highest prevalence being among isolates collected in the mid-Atlantic region and is similar to the high prevalence reported in previous studies \[[@pone.0220265.ref014]\]. To further evaluate the co-resistance among ESBL phenotypes, the resistance rates were determined for currently available oral agents that included the fluoroquinolones and TMP-SMX and the high levels of co-resistance at ≥59% have confirmed that high rates of co-resistance exist for contemporary isolates collected in 2017. Furthermore, the increased resistance to TMP-SMX is equally concerning since this resistance is plasmid-mediated with genes that not only encode enzymes such as type II dihydrofolate reductase but also additional genes that confer resistance to other antibiotic classes including the fluoroquinolones with the ability to spread between organisms \[[@pone.0220265.ref034]\].

This study not only assessed co-resistance among ESBL phenotypes but also among TMP-SMX and fluoroquinolone-resistant isolates. Not surprisingly, the TMP-SMX-resistant isolates of *E*. *coli* exhibited high co-resistance (≥ 30%) to the fluoroquinolones and cefuroxime. Also, the fluoroquinolone-resistant isolates of *E*. *coli* exhibited high co-resistance (≥ 45%) to TMP-SMX and ceforuxime. The high co-resistance among the currently available oral agents suggests that, if you lose susceptibility to one, you lose them all.

The increase in resistance to many of the currently available oral options makes the management of UTIs caused by coresistant ESBL-producing organisms a significant challenge for the clinician to treat outside of the hospital setting. Fosfomycin is one oral option that has seen increased use for the treatment of uncomplicated UTIs but was not tested in this study because of the requirement for testing by agar dilution and represents a limitation of the current study. Current methods to identify fosfomycin-resistant *E*. *coli* in urine can give very different results highlighting a need to more accurately defined rates of resistance as fosfomycin use increases \[[@pone.0220265.ref035]\]. While nitrofurantoin is another oral option for uncomplicated UTIs and is active against *E*. *coli* it is less active against *K*. *pneumoniae* and *P*. *mirbilis* that are also implicated in complicated UTI's \[[@pone.0220265.ref036]\]. Although the results of this study show that the intravenous carbapenems remain very active against most UTI isolates of *E*. *coli* with little or no carabapenem resistance, no oral options with the spectrum and potency of the carbapenems are currently available. While the development of new and systemic agents have been directed to the treatment of carbapenem-resistant Enterobacteriaceae UTIs, little or no effort has been dedicated to the development of new oral options for the treatment of UTIs caused by ESBL-producing and fluoroquinolone-resistant organisms. The development of new oral options present additional challenges, since they must be stable in solid form, and possess the appropriate pharmacodynamic properties once adequately dissolved and adsorbed in the GI tract, these agents need to reach the site of infection. Oral agents with the spectrum and potency of the intravenous carbapenems would address a substantial unmet need for new options to treat multi-drug-resistant pathogens implicated in complicated UTIs. In particular, the carbapenems are inherently stable to the ESBL and Class C (AmpC) β-lactamases, present in organisms that are prevalent among common Gram-negative UTI pathogens \[[@pone.0220265.ref037]\].

10.1371/journal.pone.0220265.r001
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We would appreciate receiving your revised manuscript by 30 November 2019. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Adriano Gianmaria Duse, MD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

1\. We noticed you have some minor occurrence(s) of overlapping text with the following previous publication(s), which needs to be addressed:

<https://aac.asm.org/content/61/11/e01045-17>

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed.

2\. Thank you for including your competing interests statement; \"Ian Critchley, Nicole Cotroneo and Michael J. Pucci are employees of Spero Therapeutics. Rodrigo Mendes is an employee of JMI Laboratories\"

We note that one or more of the authors are employed by a commercial company: name of commercial company.

Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>
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Response to reviewer comments:

Page 5 Bacterial isolates: If this information is available, it would be useful to state what proportion of isolates were from community-acquired infections and what proportion were from hospital-acquired infections; also, from which anatomical sites were these organisms isolated? If this is not possible, state that these are from both settings and/or that sites are unknown, respectively. Reference 20 is not clear regarding this issue.

Authors' response: The isolates that were tested represent both nosocomial and community-acquired infections from both uncomplicated and complicated UTIs. Unfortunately, we do not have access to enough demographic data to be able to separate isolates from community versus hospital-acquired infections. We have added information on anatomical sites with the majority of the organisms being isolated from a urine culture and 132 isolates being isolates from patients with the Foley catheter.

Page 5 Susceptibility testing: Add the CLSI M100-S28 in the references

Authors' response: This has been added to the reference list

Page 5 Resistance subsets: Consider stating which beta-lactamase genes in addition to blaCTX-M-15 were screened for. Furthermore, further characterisation of a common genotype, blaCTX-M15, could explain the persistence of these specific isolates in causing infections.

Authors' response: The isolates were screened in silico for narrow and extended spectrum β-lactamases, including carbapenemases. We have also added a comment stating that the usual β -lactamase profiles observed in these studies have been previously published (references added). \[Mendes et al., 2019 doi: 10.1093/ofid/ofz004, Castenheira et al., 2019 doi: 10.1128/AAC.00160-19 and Mendes et al., 2019 doi: 10.1089/mdr.2019.0198\].

Page 7 Susceptibility of all UTI isolates: Use the term \"resistance/resistant\" with the appropriate % consistently rather than interchanging it with \"non-susceptible\".

Authors' response: Changes made to substitute the non-susceptible rates with resistance rates

Page 7 Prevalence of ESBL phenotypes Figure 2: Consider adding amikacin to figure 2. The high rate of amikacin susceptibility in the ESBL subset provides a carbapenem-sparing treatment option.

Authors' response: Figure 2 has been amended to include amikacin.

Page 8 Figure 3: Showing ertapenem resistance rates would yield more useful information than meropenem does. It is clear that all isolates (ESBL and non-ESBL) are meropenem susceptible from Table 1. Ertapenem is a narrower spectrum carbapenem and where possible should be used preferentially.

Authors' response: Yes, we agree but unfortunately not all the 287 ESBL phenotypes of E. coli were tested against ertapenem (only 141 isolates had available susceptibility results for ertapenem) so we selected meropenem as a representative carbapenem since data was available for all 287 ESBL phenotypes for these three drugs.

Page 8 Co-resistance among fluoroquinolone-resistant Table 2: Consider adding the amoxicillin-clavulanate data.

Authors' response: Although only 8.6% of the levofloxacin-resistant isolates were resistant to amoxicillin-clavulanate, 34.3% of the isolates displayed were in the intermediate category that would not be reflected in the current presentation of the table and was a factor in our reason not to include.

Page 8 Susceptibility of blaCTX-M-15 genotypes: State what % the 151 represents of the total ESBL isolates. If any other predominating beta-lactamase type was found, add this information. If not, state this.

Authors' response: This been added to the text to highlight that CTX-M-15 was the most prevalent accounting for 59% of the ESBL phenotypes of E. coli. Also highlighted that OXA-1/30 was the next most prevalent but in most isolates was co-expressed with CTX-M-15.

Page 8 Susceptibility of blaCTX-M-15 genotypes Table 3: Correct year in title of Table 3 (2017 rather than 2016).

Authors' response: This has now been corrected to reflect 2017

Page 8 Susceptibility of blaCTX-M-15 genotypes Line 221: Should read \"of the carbapenems\" not \"carbapenem\".

Authors' response: This has been corrected

Page 9 Paragraph 2: Comment on the % blaCTX-M-15 found.

Authors' response: Added the following text: "Furthermore, blaCTX-M-15 was the most prevalent genotype among the UTI isolates of E. coli accounting for 59% of all the ESBL phenotypes

Page 10: Nitrofurantoin and fosfomycin data are not presented-add this as a limitation of the study. Authors discuss the need for new oral antibiotics particularly from carbapenem class but perhaps testing of fosfomycin would have shown susceptibility among these pathogens. Fosfomycin is an old antibiotic, used as an oral treatment for uncomplicated urinary tract infections. Fosfomycin has been shown to have activity against some resistant uropathogens suggesting that this antibiotic may provide a useful option for the treatment of patients with difficult-to-treat-infections.

Authors' response: We have added some text to the discussion regarding fosfomycin and nitrofurantoin as oral options for uncomplicated UTI. We included an explanation of why fosfomycin was not tested because of the requirement for agar dilution and therefore a limitation of the current study. Also included a sentence on nitrofurantoin and although a good option of uUTIs caused by E. coli it is not suitable for complicated UTIs where other pathogens such as K. pneumoniae and P. mirabilis are not well covered with this agent.

Additional Author Response to Reviewer Questions:

1\. We noticed you have some minor occurrence(s) of overlapping text with the following previous publication(s), which needs to be addressed:

<https://aac.asm.org/content/61/11/e01045-17>

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed.

Authors' response: All the overlapping text is from the methods section only and there is no duplicated text from outside the Methods section. Both studies were conducted in the same laboratory and used the same methods to molecularly characterize the isolates. To make it clear we have added a reference citation in the methods section to the article by Sader et al. (<https://aac.asm.org/content/61/11/e01045-17>) to reference the methods used in that study.

2\. Thank you for including your competing interests statement; \"Ian Critchley, Nicole Cotroneo and Michael J. Pucci are employees of Spero Therapeutics. Rodrigo Mendes is an employee of JMI Laboratories\"

We note that one or more of the authors are employed by a commercial company: name of commercial company.

Authors' response: The companies listed above are still relevant as described above for all the authors

3\. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Authors' response: Our respective employers (Spero Therapeutics and JMI Laboratories) did not have any role in the study design and only provided financial support in the form of salaries and research materials. All authors played an equal role in the design and analyses and presentation of the data arising from this surveillance study.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Authors\' response: We confirm our adherence to all PLOS ONE policies on sharing data and materials and provide the following statement \"This does not alter our adherence to PLOS ONE policies on sharing data and materials.\" (as detailed in your guide for authors <http://journals.plos.org/plosone/s/competing-interests>)

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>
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Dear Dr. Critchley

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Adriano Gianmaria Duse, MD

Academic Editor
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The burden of antimicrobial resistance among urinary tract isolates of *Escherichia coli* in the United States in 2017

Dear Dr. Critchley:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Adriano Gianmaria Duse

Academic Editor
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